Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition-Reference-Cited by-同舟云学术

Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition

Published:2012-10 Issue:2 Volume:526 Page:206-218
ISSN:0003-9861
Container-title:Archives of Biochemistry and Biophysics
language:en
Short-container-title:Archives of Biochemistry and Biophysics

Author:

Croasdale Rebecca,Wartha Katharina,Schanzer Juergen M.,Kuenkele Klaus-Peter,Ries Carola,Mayer Klaus,Gassner Christian,Wagner Martina,Dimoudis Nikolaos,Herter Sylvia,Jaeger Christiane,Ferrara Claudia,Hoffmann Eike,Kling Lothar,Lau Wilma,Staack Roland F.,Heinrich Julia,Scheuer Werner,Stracke Jan,Gerdes Christian,Brinkmann Ulrich,Umana Pablo,Klein Christian

Publisher

Elsevier BV

Subject

Molecular Biology,Biochemistry,Biophysics

Reference39 articles.

1. The Type 1 Insulin-Like Growth Factor Receptor Pathway

2. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights

3. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models

4. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and engineering of bispecific antibodies: insights and practical considerations;Frontiers in Bioengineering and Biotechnology;2024-01-25

2. GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy;Antibody Therapeutics;2024-01

3. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats;mAbs;2023-03-20

4. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity;Scientific Reports;2022-10-26

5. Glofitamab. Anti-CD20 T-cell-engaging bispecific antibody, Treatment of non-Hodgkin lymphoma;Drugs of the Future;2022